Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BYCC-BY - Uznanie autorstwa
 

Hybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy

cris.lastimport.scopus2024-02-12T20:45:52Z
dc.abstract.enSuperparamagnetic iron oxide nanoparticles (SPIONs) are widely used for biomedical applications for their outstanding properties such as facile functionalization and doping with different metals, high surface-to-volume ratio, superparamagnetism, and biocompatibility. This study was designed to synthesize and investigate multifunctional nanoparticle conjugate to act as both a magnetic agent, anticancer immunological drug, and radiopharmaceutic for anticancer therapy. The carrier, 166Ho doped iron oxide, was coated with an Au layer, creating core-shell nanoparticles ([166Ho] Fe3O4@Au. These nanoparticles were subsequently modified with monoclonal antibody trastuzumab (Tmab) to target HER2+ receptors. We describe the radiobioconjugate preparation involving doping of a radioactive agent and attachment of the organic linker and drug to the SPIONs’ surface. The size of the SPIONs coated with an Au shell measured by transmission electron microscopy was about 15 nm. The bioconjugation of trastuzumab onto SPIONs was confirmed by thermogravimetric analysis, and the amount of two molecules per one nanoparticle was estimated with the use of radioiodinated [131I]Tmab. The synthesized bioconjugates showed that they are efficient heat mediators and also exhibit a cytotoxic effect toward SKOV-3 ovarian cancer cells expressing HER2 receptors. Prepared radiobioconjugates reveal the high potential for in vivo application of the proposed multimodal hybrid system, combined with magnetic hyperthermia and immunotherapy against cancer tissues.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorWolski, Marcin
dc.contributor.authorGawęda, Weronika
dc.contributor.authorMajkowska-Pilip, Agnieszka
dc.contributor.authorOsial, Magdalena
dc.contributor.authorKrysiński, Paweł
dc.contributor.authorŻuk, Michał
dc.contributor.authorBilewicz, Aleksander
dc.date.accessioned2024-01-25T03:31:16Z
dc.date.available2024-01-25T03:31:16Z
dc.date.copyright2021-11-02
dc.date.issued2021
dc.description.accesstimeBEFORE_PUBLICATION
dc.description.financeŚrodki finansowe, o których mowa w art. 365 pkt. 2 ustawy
dc.description.number11
dc.description.versionFINAL_PUBLISHED
dc.description.volume13
dc.identifier.doi10.3390/PHARMACEUTICS13111843
dc.identifier.issn1999-4923
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/108766
dc.identifier.weblinkhttps://www.mdpi.com/1999-4923/13/11/1843/pdf
dc.languageeng
dc.pbn.affiliationchemical sciences
dc.relation.ispartofPharmaceutics
dc.relation.pagesart. no. 1843
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.enSPION
dc.subject.enRadio-labeled nanoparticles
dc.subject.enAnticancer therapy
dc.subject.enMagnetic hyperthermia
dc.subject.enDrug delivery
dc.subject.enTrastuzumab
dc.subject.enSuperparamagnetic nanoparticles
dc.subject.enMultimodal therapy
dc.titleHybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy
dc.typeJournalArticle
dspace.entity.typePublication